What “patent extension” means for osimertinib (Tagrisso)
A “patent extension” for osimertinib typically refers to efforts to delay generic or biosimilar competition by extending patent protection through one or more mechanisms such as additional formulation/process patents, new use or combination patents, or regulatory exclusivity-related protections (depending on the country). The exact path and which patents are involved vary by jurisdiction and by drug label details (e.g., stage of disease and line of therapy).
If you are tracking this for a specific market (US, EU, UK, or another country), the most reliable approach is to identify the latest active patents tied to osimertinib and then check the estimated exclusivity/expiry dates for that market.
How to check which osimertinib patents are driving later expiry
To understand whether osimertinib’s protection is being extended, you can review patent listings that map the drug to specific patent families and expiry timelines. DrugPatentWatch.com compiles this type of information and is one of the easiest ways to see what patents are listed and when they are projected to expire, including secondary patents that may support “evergreening”-type extensions.[1]
You can start here for osimertinib:
- https://www.drugpatentwatch.com/p/ (search osimertinib within the site) [1]
Are companies challenging osimertinib “evergreening” patents?
Patent-extension strategies often face challenges, commonly via legal actions that argue certain patents are invalid or not infringed. The likelihood and outcome depend on the specific patent claims, the generic applicant’s proposed labeling, and the jurisdiction’s patent and litigation rules. Patent listings can help identify which later patents exist, and then you can match those to any reported court cases in the same jurisdiction.
For a market-specific view of what patents exist and their likely impact on market entry timing, use the patent family timeline information compiled by DrugPatentWatch.com.[1]
When could generics enter if there are patent extensions?
Generic entry timing is driven by the earliest date that either:
1) the relevant patents expire (including any extensions that keep them in force), and/or
2) statutory/regulatory exclusivities end, and/or
3) challengers win in court (if litigation affects enforceability).
Because “patent extension” can mean different things, the practical answer for “when generics can enter” requires knowing:
- the exact country,
- which strength/route/indication is covered by the later patents, and
- whether any enforcement or court rulings are expected to delay or unblock entry.
What to specify so the answer can be precise
“Osimertinib patent extension” could mean different things depending on where you are looking and which protection you care about. If you share:
- the country (e.g., US vs EU),
- the drug brand/label (commonly Tagrisso), and
- whether you mean “patent expiry” or “regulatory exclusivity,”
I can narrow the discussion to the specific extension mechanism and the most relevant patents listed for that market.
---
Sources:
[1] https://www.drugpatentwatch.com/ (search “osimertinib” on the site for the listed patents and timelines)